AR034312A1 - Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna - Google Patents

Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna

Info

Publication number
AR034312A1
AR034312A1 ARP020101499A ARP020101499A AR034312A1 AR 034312 A1 AR034312 A1 AR 034312A1 AR P020101499 A ARP020101499 A AR P020101499A AR P020101499 A ARP020101499 A AR P020101499A AR 034312 A1 AR034312 A1 AR 034312A1
Authority
AR
Argentina
Prior art keywords
antigen
vaccine composition
preparation
hpv
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ARP020101499A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AR034312A1 publication Critical patent/AR034312A1/es
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Una composición de vacuna que comprende: (a) al menos un antígeno del virus de la inmunodeficiencia humana (VIH); y uno o los dos siguientes: (b) al menos un antígeno del virus del herpes simplex (VHS) y (c) al menos un antígeno del virus de papiloma humano (VPH). El antígeno de VIH se puede seleccionar entre el grupo compuesto por gp160, gp120, nef, tat, un aproteína de fusión nef-tat ó tat-nef, gag, pol o derivados inmunológicamente activos de los mismos; el antígeno de VPH se puede seleccionar entre el grupo compuesto por L1, L2, E6 y E7 o combinaciones de los mismos, opcionalmente en forma de una proteína de fusión o un truncado; y el antígeno de VHS puede ser gD de VHS-2 o un truncado del mismo. Un kit de vacunación que comprende dicha composición de vacuna. Uso de un antígeno de VPH y de VHS para la preparación de una composición de vacuna para la prevención o tratamiento de la infección o enfermedad por VIH o VHS. Un procedimiento para la preparación de la composición de vacuna que comprende combinar al menos un antígeno del virus de inmunodeficiencia humana (VIH) con uno o los dos siguientes: i) al menos un antígeno del virus del herpes simplex (VHS); y ii) al menos un antígeno del virus de papiloma humano (VPH).
ARP020101499A 2001-04-27 2002-04-25 Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna Withdrawn AR034312A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0110431A GB0110431D0 (en) 2001-04-27 2001-04-27 Novel compounds

Publications (1)

Publication Number Publication Date
AR034312A1 true AR034312A1 (es) 2004-02-18

Family

ID=9913641

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101499A Withdrawn AR034312A1 (es) 2001-04-27 2002-04-25 Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna

Country Status (20)

Country Link
US (1) US20040131638A1 (es)
EP (1) EP1381390A2 (es)
JP (1) JP2004531540A (es)
KR (1) KR20040030599A (es)
CN (1) CN1522153A (es)
AR (1) AR034312A1 (es)
AU (1) AU2002310802B2 (es)
BR (1) BR0209161A (es)
CA (1) CA2445310A1 (es)
CZ (1) CZ20032942A3 (es)
GB (1) GB0110431D0 (es)
HU (1) HUP0303942A3 (es)
IL (1) IL158428A0 (es)
MX (1) MXPA03009698A (es)
MY (1) MY134041A (es)
NO (1) NO20034695L (es)
NZ (1) NZ529039A (es)
PL (1) PL367134A1 (es)
WO (1) WO2002087614A2 (es)
ZA (1) ZA200308188B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1588714A2 (en) 1998-10-16 2005-10-26 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0405480D0 (en) * 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them
JP2008502633A (ja) * 2004-06-16 2008-01-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
WO2008082719A2 (en) * 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
CA2663109A1 (en) 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsylvania Hsv-1 and hsv-2 vaccines and methods of use thereof
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US9284355B2 (en) 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
JP5726727B2 (ja) * 2008-05-26 2015-06-03 カディラ・ヘルスケア・リミテッド 麻疹−ヒトパピローマ混合ワクチン
KR101652060B1 (ko) * 2008-12-25 2016-08-29 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 재조합 닭 전염성 코라이자 백신 및 그 제조방법
KR101655964B1 (ko) * 2011-08-19 2016-09-08 임모탈 스피릿 리미티드 항체 및 항체 함유 조성물
BR112017008280A2 (pt) * 2014-10-24 2018-01-02 Hpvvax, Llc. método para o tratamento de um paciente
JP2019506435A (ja) * 2016-02-27 2019-03-07 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
WO2018124615A1 (ko) 2016-12-26 2018-07-05 재단법인 목암생명과학연구소 대상포진 백신 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ES2337017T3 (es) * 1999-10-13 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Procedimiento para obtener respuestas inmunitarias celulares de proteinas.

Also Published As

Publication number Publication date
WO2002087614A2 (en) 2002-11-07
JP2004531540A (ja) 2004-10-14
WO2002087614A3 (en) 2003-04-24
NZ529039A (en) 2005-02-25
MY134041A (en) 2007-11-30
ZA200308188B (en) 2005-01-21
NO20034695D0 (no) 2003-10-20
MXPA03009698A (es) 2004-01-29
CZ20032942A3 (cs) 2004-12-15
EP1381390A2 (en) 2004-01-21
NO20034695L (no) 2003-12-03
HUP0303942A2 (hu) 2004-03-01
KR20040030599A (ko) 2004-04-09
BR0209161A (pt) 2004-08-03
HUP0303942A3 (en) 2005-11-28
AU2002310802B2 (en) 2005-03-24
CN1522153A (zh) 2004-08-18
IL158428A0 (en) 2004-05-12
GB0110431D0 (en) 2001-06-20
CA2445310A1 (en) 2002-11-07
US20040131638A1 (en) 2004-07-08
PL367134A1 (en) 2005-02-21

Similar Documents

Publication Publication Date Title
AR034312A1 (es) Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna
Krowka et al. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro.
Goepfert et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
Excler et al. Novel directions in HIV-1 vaccines revealed from clinical trials
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
PE20060149A1 (es) Formulacion farmaceutica para tratar la infeccion por vih
ES2177695T3 (es) Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.
DE69131200T2 (de) Herpes simplex virus vp16 impfstoffe
Fomsgaard HIV-1 DNA vaccines
Hsu et al. A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge
AR026637A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para uso en vacas gestantes
Locher et al. Short Communication Antibody and Cellular Immune Responses in Breakthrough Infection Subjects after HIV Type 1 Glycoprotein 120 Vaccination
FI970786A (fi) 4-/2-amino-6-(syklopropyyliamino)-9H-purin-9-yyli)-2-syklopenteeni-1-metanoli-sukkinaatti viruksia torjuvana aineena
Moingeon et al. Therapeutic vaccines against infectious diseases
WO2007018550A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
ES2500265T3 (es) Proteína Tat Oyi mutada para prevenir o tratar SIDA
Black AIDSVAX flop leaves vaccine field unscathed
Zagury et al. Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum—an adjuvant to antiretroviral tritherapy
Pattacini et al. Pre-exposure Prophylaxis Does Not Enhance HIV-specific T-cell Responses
Fast et al. Clinical considerations in vaccine trials with special reference to candidate HIV vaccines
Ensoli Rational vaccine strategies against AIDS: background and rationale
Lemos et al. Circulating CD4+ T-cells Are Transiently Activated Following Sigmoidoscopy or Circumcision in MSM at High Risk of HIV Infection

Legal Events

Date Code Title Description
FA Abandonment or withdrawal